Evaxion’s AI platform hits 86% precision in melanoma trial, expands to glioblastoma
Evaxion’s phase 2 trial of personalized cancer vaccine EVX-01 showed 86% of AI-identified targets triggered tumor-specific immune responses, with a 75% objective response rate after two years. Data on glioblastoma show AI-Immunology™ can identify endogenous retrovirus-derived antigens for vaccine design, expanding the platform’s cancer coverage.
1. EVX-01 Phase 2 Trial Results
In the phase 2 trial of personalized cancer vaccine EVX-01 in advanced melanoma patients, Evaxion reported 86% of AI-selected neoantigens triggered tumor-specific immune responses and achieved a 75% objective response rate at two years. The analysis showed a strong correlation between AI-prediction scores and immune response magnitude, underlining the platform’s precision and durability of T-cell activation.
2. Glioblastoma Vaccine Proof-of-Concept
New preclinical data demonstrate that AI-Immunology™ can identify endogenous retrovirus-derived antigens in glioblastoma samples, opening a novel antigen source for vaccine development in tumors with low mutational burden. Collaboration with academic researchers confirmed experimental immunologic responses to these ERV-derived targets, highlighting the platform’s scalability across diverse cancer types.